Profiling and Structural Analysis of Cardenolides in Two Species of Digitalis Using Liquid Chromatography Coupled with High-Resolution Mass Spectrometry
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Butterfly Plant List
Butterfly Plant List Butterflies and moths (Lepidoptera) go through what is known as a * This list of plants is seperated by host (larval/caterpilar stage) "complete" lifecycle. This means they go through metamorphosis, and nectar (Adult feeding stage) plants. Note that plants under the where there is a period between immature and adult stages where host stage are consumed by the caterpillars as they mature and the insect forms a protective case/cocoon or pupae in order to form their chrysalis. Most caterpilars and mothswill form their transform into its adult/reproductive stage. In butterflies this case cocoon on the host plant. is called a Chrysilas and can come in various shapes, textures, and colors. Host Plants/Larval Stage Perennials/Annuals Vines Common Name Scientific Common Name Scientific Aster Asteracea spp. Dutchman's pipe Aristolochia durior Beard Tongue Penstamon spp. Passion vine Passiflora spp. Bleeding Heart Dicentra spp. Wisteria Wisteria sinensis Butterfly Weed Asclepias tuberosa Dill Anethum graveolens Shrubs Common Fennel Foeniculum vulgare Common Name Scientific Common Foxglove Digitalis purpurea Cape Plumbago Plumbago auriculata Joe-Pye Weed Eupatorium purpureum Hibiscus Hibiscus spp. Garden Nasturtium Tropaeolum majus Mallow Malva spp. Parsley Petroselinum crispum Rose Rosa spp. Snapdragon Antirrhinum majus Senna Cassia spp. Speedwell Veronica spp. Spicebush Lindera benzoin Spider Flower Cleome hasslerana Spirea Spirea spp. Sunflower Helianthus spp. Viburnum Viburnum spp. Swamp Milkweed Asclepias incarnata Trees Trees Common Name Scientific Common Name Scientific Birch Betula spp. Pine Pinus spp. Cherry and Plum Prunus spp. Sassafrass Sassafrass albidum Citrus Citrus spp. Sweet Bay Magnolia virginiana Dogwood Cornus spp. Sycamore Platanus spp. Hawthorn Crataegus spp. -
Combination of Pretreatments with Acetic Acid and Sodium Methoxide for Efficient Digoxin Preparation from Digitalis Glycosides in Digitalis Lanata Leaves
Pharmacology & Pharmacy, 2016, 7, 200-207 Published Online May 2016 in SciRes. http://www.scirp.org/journal/pp http://dx.doi.org/10.4236/pp.2016.75026 Combination of Pretreatments with Acetic Acid and Sodium Methoxide for Efficient Digoxin Preparation from Digitalis Glycosides in Digitalis lanata Leaves Yasuhiko Higashi*, Yukari Ikeda, Youichi Fujii Department of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa, Japan Received 21 April 2016; accepted 28 May 2016; published 31 May 2016 Copyright © 2016 by authors and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/ Abstract We previously developed an HPLC method for determination of lanatoside C, digoxin and α-acetyl- digoxin in digitalis glycosides isolated from Digitalis lanata leaves. Here, we present an improved HPLC-UV method to determine those compounds and deslanoside. We used the improved method to examine the effects of various pretreatments on the amounts of the four compounds isolated from the leaves, with the aim of maximizing the yield of digoxin. Leaves were extracted with 50% methanol, followed by clean-up on a Sep-Pak C18 cartridge prior to HPLC analysis. The amounts of lanatoside C, digoxin and α-acetyldigoxin per 100 mg of the leaves without pretreatment were 115.6, 7.45 and 23.8 μg, respectively (deslanoside was not detected). Pretreatment with acetic ac- id, which activated deglucosylation mediated by digilanidase present in the leaves, increased the amounts of digoxin and α-acetyldigoxin, while lanatoside C and deslanoside were not detected. Pretreatment with sodium methoxide, which hydrolyzed lanatoside C to deslanoside, increased the yields of deslanoside and digoxin, while lanatoside C and α-acetyldigoxin were not detected. -
Glycosides Pharmacognosy Dr
GLYCOSIDES PHARMACOGNOSY DR. KIBOI Glycosides Glycosides • Glycosides consist of a sugar residue covalently bound to a different structure called the aglycone • The sugar residue is in its cyclic form and the point of attachment is the hydroxyl group of the hemiacetal function. The sugar moiety can be joined to the aglycone in various ways: 1.Oxygen (O-glycoside) 2.Sulphur (S-glycoside) 3.Nitrogen (N-glycoside) 4.Carbon ( Cglycoside) • α-Glycosides and β-glycosides are distinguished by the configuration of the hemiacetal hydroxyl group. • The majority of naturally-occurring glycosides are β-glycosides. • O-Glycosides can easily be cleaved into sugar and aglycone by hydrolysis with acids or enzymes. • Almost all plants that contain glycosides also contain enzymes that bring about their hydrolysis (glycosidases ). • Glycosides are usually soluble in water and in polar organic solvents, whereas aglycones are normally insoluble or only slightly soluble in water. • It is often very difficult to isolate intact glycosides because of their polar character. • Many important drugs are glycosides and their pharmacological effects are largely determined by the structure of the aglycone. • The term 'glycoside' is a very general one which embraces all the many and varied combinations of sugars and aglycones. • More precise terms are available to describe particular classes. Some of these terms refer to: 1.the sugar part of the molecule (e.g. glucoside ). 2.the aglycone (e.g. anthraquinone). 3.the physical or pharmacological property (e.g. saponin “soap-like ”, cardiac “having an action on the heart ”). • Modern system of naming glycosides uses the termination '-oside' (e.g. sennoside). • Although glycosides form a natural group in that they all contain a sugar unit, the aglycones are of such varied nature and complexity that glycosides vary very much in their physical and chemical properties and in their pharmacological action. -
Cardiovascular System
Dr Arpita Shrivastav CARDIOVASCULAR SYSTEM Cardiac Tonic – These are the drugs which stimulate the heart. Eg. Cardiac Glycosides. Cardiac Glycosides – It represents a family of compound which are derived from, foxglove plant (digitalis purpurea). William withrin Ist used it to treat dropsy which occur due to heart failure. Cardiac glycosides are compounds which consist of sugar part attached with non sugar part (steroid nucleus & lactone ring) with the help of O2 molecule. Lactone ring and cyclo pentane perhydro phenanthren ring are aglycone part where as sugar part is the glycone part. Source Plants (1) Digoxin D. lanata (2) Digitoxin D. purpurea (3) Gitaxin D. purpurea (4) Gilalin D. purpurea (5) Strophanthin K Strophanthus combe (6) Ouabain S. gratus (7) Thevetin Thevetia herefolia (8) Bufotoxin Bufovulgaris Structural Effect – Sugar part attached at C3 affect Pharmacokinetics (PK) properties of glycosides like water solubility, self penetrability duration of action etc. Pharmacodynamics properties like cardiac activity depends on lactone ring and steroid nucleus. Mode of Action (MOA) – In heart the process of membrane depolarization or repolarization is controlled by Na+, K+ and Ca++ ions. When action potential is generated Na+ enters inside the membrane along with Ca++ (Na+ - Ca++ exchanger) (3 Na+ - 2 Ca++). The higher Intracellular Ca++ conc. Results in efflux of K+, the reestablishment of action potential occur by reverse of Na+ - K+ exchange which require energy provided by an enzyme. Na+ K+ ATPas Cardiac. Glycosides inhibit this enzyme. Which lead to reduce Na+k+ exchange, intracellular Na+ and Ca++ conc. Which further result in in myocardial contraction or +ve ionotropic effect. -
Chemistry, Spectroscopic Characteristics and Biological Activity of Natural Occurring Cardiac Glycosides
IOSR Journal of Biotechnology and Biochemistry (IOSR-JBB) ISSN: 2455-264X, Volume 2, Issue 6 Part: II (Sep. – Oct. 2016), PP 20-35 www.iosrjournals.org Chemistry, spectroscopic characteristics and biological activity of natural occurring cardiac glycosides Marzough Aziz DagerAlbalawi1* 1 Department of Chemistry, University college- Alwajh, University of Tabuk, Saudi Arabia Abstract:Cardiac glycosides are organic compounds containing two types namely Cardenolide and Bufadienolide. Cardiac glycosides are found in a diverse group of plants including Digitalis purpurea and Digitalis lanata (foxgloves), Nerium oleander (oleander),Thevetiaperuviana (yellow oleander), Convallariamajalis (lily of the valley), Urgineamaritima and Urgineaindica (squill), Strophanthusgratus (ouabain),Apocynumcannabinum (dogbane), and Cheiranthuscheiri (wallflower). In addition, the venom gland of cane toad (Bufomarinus) contains large quantities of a purported aphrodisiac substance that has resulted in cardiac glycoside poisoning.Therapeutic use of herbal cardiac glycosides continues to be a source of toxicity today. Recently, D.lanata was mistakenly substituted for plantain in herbal products marketed to cleanse the bowel; human toxicity resulted. Cardiac glycosides have been also found in Asian herbal products and have been a source of human toxicity.The most important use of Cardiac glycosides is its affects in treatment of cardiac failure and anticancer agent for several types of cancer. The therapeutic benefits of digitalis were first described by William Withering in 1785. Initially, digitalis was used to treat dropsy, which is an old term for edema. Subsequent investigations found that digitalis was most useful for edema that was caused by a weakened heart. Digitalis compounds have historically been used in the treatment of chronic heart failure owing to their cardiotonic effect. -
CZECH REPUBLIC: COUNTRY REPORT to the FAO INTERNATIONAL TECHNICAL CONFERENCE on PLANT GENETIC RESOURCES (Leipzig 1996)
CZECH REPUBLIC: COUNTRY REPORT TO THE FAO INTERNATIONAL TECHNICAL CONFERENCE ON PLANT GENETIC RESOURCES (Leipzig 1996) Prepared by: Ladislav Dotlac˘il Karel Vanc˘ura Prague, April 1995 BANGLADESH country report 2 Note by FAO This Country Report has been prepared by the national authorities in the context of the preparatory process for the FAO International Technical Conference on Plant Genetic Resources, Leipzig, Germany, 17-23 June 1996. The Report is being made available by FAO as requested by the International Technical Conference. However, the report is solely the responsibility of the national authorities. The information in this report has not been verified by FAO, and the opinions expressed do not necessarily represent the views or policy of FAO. The designations employed and the presentation of the material and maps in this document do not imply the expression of any option whatsoever on the part of the Food and Agriculture Organization of the United Nations concerning the legal status of any country, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. BANGLADESH country report 3 Table of Contents CHAPTER 1 CHARACTERISTICS OF THE CZECH REPUBLIC, ITS AGRICULTURAL AND FORESTRY SECTORS 6 1.1 GENERAL INFORMATION 6 1.2 AGRICULTURE IN THE CZECH REPUBLIC 8 1.3 FORESTRY IN THE CZECH REPUBLIC 10 CHAPTER 2 INDIGENOUS PLANT GENETIC RESOURCES 12 2.1 FOREST GENETIC RESOURCES 12 2.2 WILD SPECIES AND WILD RELATIVES OF CROP PLANTS 13 2.3 LANDRACES (FARMERS‘ VARIETIES) AND OLD CULTIVARS 15 CHAPTER -
Quinidine, Beta-Blockers, Diphenylhydantoin, Bretylium *
Pharmacology of Antiarrhythmics: Quinidine, Beta-Blockers, Diphenylhydantoin, Bretylium * ALBERT J. WASSERMAN, M.D. Professor of Medicine, Chairman, Division of Clinical Pharmacology, Medical College of Virginia, Health Sciences Division of Virginia Commonwealth University, Richmond, Virginia JACK D. PROCTOR, M.D. Assistant Professor of Medicine, Medical College of Virginia, Health Sciences Division of Virginia Commonwealth University, Richmond, Virginia The electrophysiologic effects of the antiar adequate, controlled clinical comparisons are virtu rhythmic drugs, presented elsewhere in this sym ally nonexistent. posium, form only one of the bases for the selec A complete presentation of the non-electro tion of a therapeutic agent in any given clinical physiologic pharmacology would include the follow situation. The final choice depends at least on the ing considerations: following factors: 1. Absorption and peak effect times 1. The specific arrhythmia 2. Biotransformation 2. Underlying heart disease, if any 3. Rate of elimination or half-life (t1d 3. The degree of compromise of the circula 4. Drug interactions tion, if any 5. Toxicity 4. The etiology of the arrhythmia 6. Clinical usefulness 5. The efficacy of the drug for that arrhythmia 7. Therapeutic drug levels due to that etiology 8. Dosage schedules 6. The toxicity of the drug, especially in the As all of the above data cannot be presented in given patient with possible alterations in the limited space available, only selected items will volume of distribution, biotransformation, be discussed. Much of the preceding information and excretion is available, however, in standard texts ( 1 7, 10). 7. The electrophysiologic effects of the drug (See Addendum 1) 8. The routes and frequency of administration Quinidine. -
Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01 -
Malaysian STATISTICS on MEDICINE 2005
Malaysian STATISTICS ON MEDICINE 2005 Edited by: Sameerah S.A.R Sarojini S. With contributions from Goh A, Faridah A, Rosminah MD, Radzi H, Azuana R, Letchuman R, Muruga V, Zanariah H, Oiyammal C, Sim KH, Fong AYY, Tamil Selvan M, Basariah N, Hooi LS, Zaki Morad, Fadilah O, Lim V.K.E., Tan KK, Biswal BM, Lim YS, Lim GCC, Mohammad Anwar H.A, Ahmad Sabri O, Mary SC, Marzida M, Benjamin Chan TM, Suarn Singh, Zoriah A, Noor Ratna N , Abdul Razak M, Norzila Z, Shamsinah H A publication of the Pharmaceutical Services Division and the Clinical Research Centre Ministry of Health Malaysia Malaysian Statistics On Medicine 22005005 Edited by: Sameerah S.A.R Sarojini S. With contributions from Goh A, Faridah A, Rosminah MD, Radzi H, Azuana R, Letchuman R, Muruga V, Zanariah H, Oiyammal C, Sim KH, Fong AYY, Tamil Selvan M, Basariah N, Hooi LS, Zaki Morad, Fadilah O, Lim V.K.E., Tan KK, Biswal BM, Lim YS, Lim GCC, Mohammad Anwar H.A, Ahmad Sabri O, Mary SC, Marzida M, Benjamin Chan TM, Suarn Singh, Zoriah A, Noor Ratna N , Abdul Razak M, Norzila Z, Shamsinah H A publication of the Pharmaceutical Services Division and the Clinical Research Centre Ministry of Health Malaysia Malaysian Statistics On Medicine 2005 April 2007 © Ministry of Health Malaysia Published by: The National Medicines Use Survey Pharmaceutical Services Division Lot 36, Jalan Universiti 46350 Petaling Jaya Selangor, Malaysia Tel. : (603) 4043 9300 Fax : (603) 4043 9400 e-mail : [email protected] Web site : http://www.crc.gov.my/nmus This report is copyrighted. -
The Colletotrichum Destructivum Species Complex – Hemibiotrophic Pathogens of Forage and field Crops
available online at www.studiesinmycology.org STUDIES IN MYCOLOGY 79: 49–84. The Colletotrichum destructivum species complex – hemibiotrophic pathogens of forage and field crops U. Damm1*, R.J. O'Connell2, J.Z. Groenewald1, and P.W. Crous1,3,4 1CBS-KNAW Fungal Biodiversity Centre, Uppsalalaan 8, 3584 CT Utrecht, The Netherlands; 2UMR1290 BIOGER-CPP, INRA-AgroParisTech, 78850 Thiverval-Grignon, France; 3Forestry and Agricultural Biotechnology Institute (FABI), University of Pretoria, Pretoria 0002, South Africa; 4Wageningen University and Research Centre (WUR), Laboratory of Phytopathology, Droevendaalsesteeg 1, 6708 PB Wageningen, The Netherlands *Correspondence: U. Damm, [email protected], Present address: Senckenberg Museum of Natural History Görlitz, PF 300 154, 02806 Görlitz, Germany. Abstract: Colletotrichum destructivum is an important plant pathogen, mainly of forage and grain legumes including clover, alfalfa, cowpea and lentil, but has also been reported as an anthracnose pathogen of many other plants worldwide. Several Colletotrichum isolates, previously reported as closely related to C. destructivum, are known to establish hemibiotrophic infections in different hosts. The inconsistent application of names to those isolates based on outdated species concepts has caused much taxonomic confusion, particularly in the plant pathology literature. A multilocus DNA sequence analysis (ITS, GAPDH, CHS-1, HIS3, ACT, TUB2) of 83 isolates of C. destructivum and related species revealed 16 clades that are recognised as separate species in the C. destructivum complex, which includes C. destructivum, C. fuscum, C. higginsianum, C. lini and C. tabacum. Each of these species is lecto-, epi- or neotypified in this study. Additionally, eight species, namely C. americae- borealis, C. antirrhinicola, C. bryoniicola, C. -
New York Non-Native Plant Invasiveness Ranking Form
NEW YORK NON-NATIVE PLANT INVASIVENESS RANKING FORM Scientific name: Digitalis lanata Ehrh. USDA Plants Code: DILA3 Common names: Grecian foxglove Native distribution: Southeastern Europe Date assessed: February 1, 2010 Assessors: Steve Glenn, Gerry Moore Reviewers: LIISMA SRC Date Approved: March 10, 2010 Form version date: 10 July 2009 New York Invasiveness Rank: Insignificant (Relative Maximum Score <40.00) Distribution and Invasiveness Rank (Obtain from PRISM invasiveness ranking form) PRISM Status of this species in each PRISM: Current Distribution Invasiveness Rank 1 Adirondack Park Invasive Program Not Assessed Not Assessed 2 Capital/Mohawk Not Assessed Not Assessed 3 Catskill Regional Invasive Species Partnership Not Assessed Not Assessed 4 Finger Lakes Not Assessed Not Assessed 5 Long Island Invasive Species Management Area Not Present Low 6 Lower Hudson Not Assessed Not Assessed 7 Saint Lawrence/Eastern Lake Ontario Not Assessed Not Assessed 8 Western New York Not Assessed Not Assessed Invasiveness Ranking Summary Total (Total Answered*) Total (see details under appropriate sub-section) Possible 1 Ecological impact 40 (30) 3 2 Biological characteristic and dispersal ability 25 (22) 13 3 Ecological amplitude and distribution 25 (25) 13 4 Difficulty of control 10 (10) 3 b a Outcome score 100 (87) 32 † Relative maximum score 36.78 § New York Invasiveness Rank Insignificant (Relative Maximum Score <40.00) * For questions answered “unknown” do not include point value in “Total Answered Points Possible.” If “Total Answered Points Possible” is less than 70.00 points, then the overall invasive rank should be listed as “Unknown.” †Calculated as 100(a/b) to two decimal places. §Very High >80.00; High 70.00−80.00; Moderate 50.00−69.99; Low 40.00−49.99; Insignificant <40.00 Not Assessable: not persistent in NY, or not found outside of cultivation. -
Pharmaceutical Services Division and the Clinical Research Centre Ministry of Health Malaysia
A publication of the PHARMACEUTICAL SERVICES DIVISION AND THE CLINICAL RESEARCH CENTRE MINISTRY OF HEALTH MALAYSIA MALAYSIAN STATISTICS ON MEDICINES 2008 Edited by: Lian L.M., Kamarudin A., Siti Fauziah A., Nik Nor Aklima N.O., Norazida A.R. With contributions from: Hafizh A.A., Lim J.Y., Hoo L.P., Faridah Aryani M.Y., Sheamini S., Rosliza L., Fatimah A.R., Nour Hanah O., Rosaida M.S., Muhammad Radzi A.H., Raman M., Tee H.P., Ooi B.P., Shamsiah S., Tan H.P.M., Jayaram M., Masni M., Sri Wahyu T., Muhammad Yazid J., Norafidah I., Nurkhodrulnada M.L., Letchumanan G.R.R., Mastura I., Yong S.L., Mohamed Noor R., Daphne G., Kamarudin A., Chang K.M., Goh A.S., Sinari S., Bee P.C., Lim Y.S., Wong S.P., Chang K.M., Goh A.S., Sinari S., Bee P.C., Lim Y.S., Wong S.P., Omar I., Zoriah A., Fong Y.Y.A., Nusaibah A.R., Feisul Idzwan M., Ghazali A.K., Hooi L.S., Khoo E.M., Sunita B., Nurul Suhaida B.,Wan Azman W.A., Liew H.B., Kong S.H., Haarathi C., Nirmala J., Sim K.H., Azura M.A., Asmah J., Chan L.C., Choon S.E., Chang S.Y., Roshidah B., Ravindran J., Nik Mohd Nasri N.I., Ghazali I., Wan Abu Bakar Y., Wan Hamilton W.H., Ravichandran J., Zaridah S., Wan Zahanim W.Y., Kannappan P., Intan Shafina S., Tan A.L., Rohan Malek J., Selvalingam S., Lei C.M.C., Ching S.L., Zanariah H., Lim P.C., Hong Y.H.J., Tan T.B.A., Sim L.H.B, Long K.N., Sameerah S.A.R., Lai M.L.J., Rahela A.K., Azura D., Ibtisam M.N., Voon F.K., Nor Saleha I.T., Tajunisah M.E., Wan Nazuha W.R., Wong H.S., Rosnawati Y., Ong S.G., Syazzana D., Puteri Juanita Z., Mohd.